AAAAAA
Results: 26-50/52
Authors:
Gertz, MA
Lacy, MQ
Dispenzieri, A
Citation: Ma. Gertz et al., Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report, BONE MAR TR, 25(5), 2000, pp. 465-470
Authors:
Clements, IP
Olson, LJ
Scanlon, PD
Gertz, MA
Mullany, CJ
Citation: Ip. Clements et al., The effect of respiration on left ventricular diastolic filling as assessed by radionuclide ventriculography, NUCL MED C, 21(1), 2000, pp. 55-63
Authors:
Rajkumar, SV
Gertz, MA
Witzig, TE
Citation: Sv. Rajkumar et al., Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma., N ENG J MED, 343(13), 2000, pp. 972-973
Authors:
Van Gerpen, JA
Goudreau, JL
Dodick, DW
Gertz, MA
Citation: Ja. Van Gerpen et al., Amyloidosis presenting with intractable epistaxis and multiple cranial neuropathies, NEUROLOGY, 55(11), 2000, pp. 1755-1756
Authors:
Rajkumar, SV
Fonseca, R
Dispenzieri, A
Lacy, MQ
Lust, JA
Witzig, TE
Kyle, RA
Gertz, MA
Greipp, PR
Citation: Sv. Rajkumar et al., Thalidomide in the treatment of relapsed multiple myeloma, MAYO CLIN P, 75(9), 2000, pp. 897-901
Authors:
Kyle, RA
Greipp, PR
Gertz, MA
Witzig, TE
Lust, JA
Lacy, MQ
Therneau, TM
Citation: Ra. Kyle et al., Waldenstrom's macroglobulinaemia: a prospective study comparing daily withintermittent oral chlorambucil, BR J HAEM, 108(4), 2000, pp. 737-742
Authors:
Mueller, PS
Edwards, WD
Gertz, MA
Citation: Ps. Mueller et al., Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis, AM J MED, 109(3), 2000, pp. 181-188
Authors:
Grogan, M
Gertz, MA
Kyle, RA
Tajik, AJ
Citation: M. Grogan et al., Five or more years of survival in patients with primary systemic amyloidosis and biopsy-proven cardiac involvement, AM J CARD, 85(5), 2000, pp. 664
Authors:
Gertz, MA
Lacy, MQ
Lust, JA
Greipp, PR
Witzig, TE
Kyle, RA
Citation: Ma. Gertz et al., Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis, MED ONCOL, 16(2), 1999, pp. 104-109
Authors:
Fonseca, R
Hoyer, JD
Aguayo, P
Jalal, SM
Ahmann, GJ
Rajkumar, SV
Witzig, TE
Lacy, MQ
Dispenzieri, A
Gertz, MA
Kyle, RA
Greipp, PR
Citation: R. Fonseca et al., Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma, LEUK LYMPH, 35(5-6), 1999, pp. 599-605
Authors:
Gertz, MA
Lacy, MQ
Dispenzieri, A
Citation: Ma. Gertz et al., Amyloidosis, HEMAT ONCOL, 13(6), 1999, pp. 1211
Authors:
Lacy, MQ
Gertz, MA
Citation: Mq. Lacy et Ma. Gertz, Acquired Fanconi's syndrome associated with monoclonal gammopathies, HEMAT ONCOL, 13(6), 1999, pp. 1273
Authors:
Kyle, RA
Gertz, MA
Citation: Ra. Kyle et Ma. Gertz, Monoclonal gammopathies and related disorders - Preface, HEMAT ONCOL, 13(6), 1999, pp. XIII-XV
Authors:
Rajkumar, SV
Fonseca, R
Witzig, TE
Gertz, MA
Greipp, PR
Citation: Sv. Rajkumar et al., Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma, LEUKEMIA, 13(3), 1999, pp. 469-472
Authors:
Rajkumar, SV
Fonseca, R
Lacy, MQ
Witzig, TE
Therneau, TM
Kyle, RA
Litzow, MR
Gertz, MA
Greipp, PR
Citation: Sv. Rajkumar et al., Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma, J CL ONCOL, 17(5), 1999, pp. 1551-1557
Authors:
Gertz, MA
Lacy, MQ
Lust, JA
Greipp, PR
Witzig, TE
Kyle, RA
Citation: Ma. Gertz et al., Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatmentof primary systemic amyloidosis, J CL ONCOL, 17(1), 1999, pp. 262-267
Authors:
Gertz, MA
Lacy, MQ
Lust, JA
Greipp, PR
Witzig, TE
Kyle, RA
Citation: Ma. Gertz et al., Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis, AM J HEMAT, 61(2), 1999, pp. 115-119
Authors:
Rajkumar, SV
Fonseca, R
Lacy, MQ
Witzig, TE
Lust, JA
Greipp, PR
Therneau, TM
Kyle, RA
Litzow, MR
Gertz, MA
Citation: Sv. Rajkumar et al., Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma, BONE MAR TR, 24(5), 1999, pp. 497-503
Authors:
Gertz, MA
Lacy, MQ
Inwards, DJ
Chen, MG
Pineda, AA
Gastineau, DA
Greipp, PR
Lust, JA
Tefferi, A
Witzig, TE
Kyle, RA
Litzow, MR
Citation: Ma. Gertz et al., Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma, BONE MAR TR, 23(3), 1999, pp. 221-226
Authors:
Rajkumar, SV
Fonseca, R
Lacy, MQ
Witzig, TE
Lust, JA
Greipp, PR
Therneau, TM
Kyle, RA
Litzow, MR
Gertz, MA
Citation: Sv. Rajkumar et al., Beta(2)-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma, BONE MAR TR, 23(12), 1999, pp. 1261-1266
Authors:
Rajkumar, SV
Fonseca, R
Lacy, MQ
Witzig, TE
Lust, JA
Greipp, PR
Therneau, TM
Kyle, RA
Litzow, MR
Gertz, MA
Citation: Sv. Rajkumar et al., Autologous stem cell transplantation for relapsed and primary refractory myeloma, BONE MAR TR, 23(12), 1999, pp. 1267-1272
Authors:
Rajkumar, SV
Fonseca, R
Dewald, GW
Therneau, TM
Lacy, MQ
Kyle, RA
Greipp, PR
Gertz, MA
Citation: Sv. Rajkumar et al., Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma, CANC GENET, 113(1), 1999, pp. 73-77
Authors:
Gertz, MA
Lacy, MQ
Dispenzieri, A
Citation: Ma. Gertz et al., Amyloidosis: Recognition, confirmation, prognosis, and therapy, MAYO CLIN P, 74(5), 1999, pp. 490-494
Authors:
Kyle, RA
Gertz, MA
Greipp, PR
Witzig, TE
Lust, JA
Lacy, MQ
Therneau, TM
Citation: Ra. Kyle et al., Long-term survival (10 years or more) in 30 patients with primary amyloidosis, BLOOD, 93(3), 1999, pp. 1062-1066
Authors:
Al Suwaidi, J
Velianou, JL
Gertz, MA
Cannon, RO
Higano, ST
Holmes, DR
Lerman, A
Citation: J. Al Suwaidi et al., Systemic amyloidosis presenting with angina pectoris, ANN INT MED, 131(11), 1999, pp. 838-841